Of the BC samples, 44% (8/18) registered at least one analyte above the highest standard curve concentration, observed with A1AT (n = 7/18), IL-8 (n = 5) and/or ANG (n = 2); in Control samples, a single instance was observed of a biomarker (i.e., A1AT) exceeding the assay’s dynamic range. Here, CXCL8 is linked to breast cancer.